natgillin/translations-raw huggingface dataset:
The pharmaceutical composition of Claim 4, wherein the composition further comprises a steroidal anti-inflammatory agent. The pharmaceutical composition of Claim 5, wherein the steroidal anti-inflammatory agent is 6a,9a-difluoro-17a-[(2-furanylcarbonyl)oxy]-11B-hydroxy-16a-methyl-3-oxoandrosta-1,4-diene-17B-carbothioic acid S -fluoromethyl ester or a solvate thereof. The pharmaceutical composition of Claim 5, wherein the steroidal anti-inflammatory agent is Fluticasone Propionate. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što je steroidno protuupalno sredstvo S-fluormetilni ester 6a,9a-difluor-17a-[(2-furanilkarbonil)oksi]-11B-hidroksi-16a-metil-3-oksoandrosta-1,4-dien-17B-karbotiojske kiseline, ili njegov solvat. Farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što je steroidno protuupalno sredstvo flutikazon-propionat.
Figure 10 shows t (cm2/g) against SDS concentration (mg/µg) during diafiltration, and Figure 11 converts t into MW (kDa). 
Slika 10 pokazuje € (cm'/g) prema koncentraciji SDS (mg/ug) za vrijeme diafiltracije, a Slika 11 konvertira ru MW (kDa).
is a group having the structure: 
R* je skupina sa strukturom:
“Alkenyl” means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. 
"alkenil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu dvostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i sadrži 2 do 15 atoma ugljika u lancu;
contacting the polypeptides with a monoclonal antibody comprising a heavy chain variable region comprising complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOs: 95, 99, and 101 and a light chain variable region comprising CDRs comprising the amino acid sequences of SEQ ID NOs: 103, 108, and 113 that specifically binds to a fragment of said SNAP-25 polypeptide comprising the C-terminal amino acid sequence of SEQ ID NO: 38, wherein said antibody binds an epitope of said fragment comprising the carboxylated carboxyl-terminal glutamine with an equilibrium disassociation constant of less than 0.450 nM and wherein said antibody has an association rate constant for an epitope of intact SNAP-25 polypeptide comprising SEQ ID NO: 5 of less than 1×101 M−1 s−1; and 
Postupak u skladu s patentnim zahtjevom 7, pri čemu sendvič imunološki test koristi elektrokemiluminiscenciju ili kemiluminiscenciju kao korak postupka otkrivanja. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu (i) anti-SNAP-25 antitijelo sadrži varijabilnu regiju teškog lanca koja sadrži komplementarne određujuće regije (CDRs) koje sadrže sekvence aminokiselina najmanje jedne od SEQ ID NOs: 95, 99 i 101 i varijabilnu regiju lakog lanca koja sadrži CDRs koji sadrže sekvence aminokiselina najmanje jedne od SEQ ID NOs: 103, 108 i 113ili
A pharmaceutical combination of Claim 25 wherein the agent used to treat substance abuse and addictive disorders is selected from selective serotonin reuptake inhibitors; methadone; buprenorphine; nicotine; and bupropion. 
Farmaceutski sastav Zahtjeva 25, naznačen time, da je sredstvo koje se upotrebljava za liječenje zlouporabe tvari i poremećaja ovisnosti odabrano od inhibitora selektivne reapsorpcije serotonina, metadona, buprenorfina, nikotina i bupropiona.
A process for preparing a compound of formula V wherein PG is an amino protecting group, comprising reducing a compound of formula VI: 
Postupak dobivanja spoja formule V, gdje je PG zaštima skupina za amino, naznačen time što se sastoji u reduciranju spoja formule VI:
is selected from the following: wherein: 
R? je odabran od slijedećeg: 10
A protein layer according to claim 9, wherein said third oligomer assembly belongs to a dihedral point group of order O, said third oligomer assembly being the same as said first oligomer assembly. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time, da navedeni treći skup oligomera pripada dihedralnoj točkinoj grupi reda O, pri čemu je treći skup oligomera jednak kao i navedeni prvi skup oligomera.
is selected from the group consisting of H, a polyethylene glycol polymer wherein n can range between 1 and 5, 
R, je odabran iz skupine koju čine H, polietilen glikol polimer O O ZO
A general problem with mounting containers with the outlet end facing downwards is that the opening and closing of the container is difficult without risking that the content will be spilled. 
Općeniti problem kod montiranja spremnika s izlaznim krajem okrenutim prema dolje je teško otvaranje i zatvaranje spremnika bez opasnosti od prolijevanja sadržaja.
The N-protected starting materials necessary for this process can be prepared as follows:- or 
N-zaštitni polazni materijali koji su potrebni za ovaj postupak mogu se načiniti kako slijedi:
The lozenge of claim 1 wherein the method further comprises the step of adding a pH adjustment agent to the mixture of steps (a), (b), (c) or (d) to adjust the pH to approximately 7.5-9.0. 
Postupak prema patentnom zahtjevu 41 ili 42, naznačen time što sadrži i dodatne korake: b1) dodavanje jednog ili više puferiranih sredstava; 1 b2) dodavanje sredstva za podešavanje pH vrijednosti da bi se pH podesila do približno 7.5-9.0.
The composition of embodiment 7, wherein the composition is for use in a method of reducing disease incidence or disease severity. The composition of any preceding embodiment, wherein the composition is for use in a method of reducing IL-17 production or reducing Th17 cell differentiation in the treatment or prevention of a disease or condition mediated by IL-17 or the Th17 pathway. 
Sastav za upotrebu prema bilo kojem prethodnom zahtjevu, gdje je sastav za upotrebu u postupku smanjenja proizvodnje IL-17 ili smanjenja diferencijacije Th17 stanica u liječenju ili prevenciji astme koja je posredovana s IL-17 ili putem Th17; i/ili gdje je sastav za upotrebu kod pacijenta s povećanim razinama IL-17 ili Th17 stanicama.
A pharmaceutical composition comprising a CNP variant of any of the preceding claims, and a pharmaceutically acceptable excipient, carrier, or diluent. 
Farmaceutski pripravak naznačen time da sadrži CNP varijantu prema zahtjevu 1, te farmaceutski prihvatljivu pomoćnu tvar, nosač ili dodatak otapalu.
A human IL-4 specific monoclonal antibody comprising a polypeptide of SEQ ID NO:1 and a polypeptide of SEQ ID NO:2. 
Monoklonalno protutijelo specifično za humani IL-4, naznačeno time, da obuhvaća polipeptid od SEQ ID NO:1 i polipeptid od SEQ ID NO:2.
The cooking aid of claim 1, wherein the fat is selected from the group consisting of pork fat, tallow, lard, bone fats, butter, fractionated palm fat, and any fully or partially hydrogenated or inter-esterified palm oil, cotton seed oil, peanut oil, soya oil, olive oil, sunflower oil, and rape seed oil. 
Kuhinjsko pomagalo u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što se mast bira iz skupine koju čine svinjska mast, loj, salo, koštane masti, maslac, frakcionirana palmina mast, te bilo koje posve ili djelomično hidrogenirano ili interesterificirano palmino ulje, ulje pamukovog sjemena, kikirikijevo ulje, sojino ulje, maslinovo ulje, suncokretovo ulje ili repičino ulje.
a floor which slopes downwards from the back wall to the front wall along the longitudinal axis of the bed and inwards from each of the side walls to a trough line centered along said longitudinal axis of the sludge drying bed; 
(b) pod koji je nagnut prema dolje od stražnjeg zida do prednjeg zida po uzdužnoj osi ležišta i prema unutra od svakog od bočnih zidova do prolazne linije centrirane na navedenoj uzdužnoj osi ležišta za sušenje mulja
providing a solution of N -benzoyl-staurosporine in a solvent; 
pribavljanje otopine N-benzoil-staurosporina u otapalu;
Cable 64 can communicate the voltage reading of voltmeter 62 to a controller 80 (see Figure 2). 
Kabl 64 prenosi očitavanje voltmetra 62 do upravljačkog elementa 80 (vidjeti sliku 2).
Since the sample actually enters in the protected environment of the interior of the tube, the risk of the sample being destroyed is greatly limited compared to the standard methods for taking a cervical smear. 
Budući da uzorak u stvari ulazi u zaštićeni prostor u unutrašnjosti cijevi, opasnost da se uzorak uništi je znatno smanjena u usporedbi sa standardnim postupcima za uzimanje brisa iz grlića maternice.
A stable, freeze-dried composition having an amorphous structure and comprising the peptides of SEQ ID NOS: 1 to 4, thioglycerol and trehalose. 
Stabilan, liofilizirani pripravak, naznačen time, da sadrži peptide SEQ ID Br.: 1 do 4, tioglicerol i trehalozu.
Thus, it is possible to prepare a rapamycin derivative that is selectively activated at the 31-position, the 42-position, or both. 
Prema tome, moguće je pripremiti derivat rapamicina koji je selektivno aktiviran na položaju 31, položaju 42 ili na oba položaja.
Thus, in a first aspect, the invention provides a series of compounds according to formula I: wherein, 
Prema tome, prvi aspekt ovog izuma je osiguravanje serije spojeva formule I: formula 1
wherein a compound of formula (4): is allowed to react with hydrogen in the presence of a 5% palladium/1% iron catalyst on carbon which is water-wetted, in suspension in a solvent, such as methanol for example, thereby providing a compound of formula (5). 
O. (4) ' ostavljen da reagira s vodikom u prisutnosti 5% paladijevog/1% željezovog katalizatora na ugljiku koji je navlažen vodom, u otapalu, čime se dobiva spoj s formulom (5).
Such kegs are intended for expensive and elaborate dispensing assemblies comprising draught beer coolers, carbon dioxide cartridges, etc., for cooling and dispensing the beverage from the container. 
Takove bačve su predviđene za skupe i fino izrađene sklopove za točenje, koji obuhvaćaju uređaj za hlađenje piva iz bačve, umetke s ugljičnim dioksidom, itd., za hlađenje i točenje pića iz spremnika.
It is also possible that such pressing elements are not in direct contact with one of the walls of the container but that they deform, for example, an annular and flexible ring from its inside and that this ring will deform to press the walls of the cup body and shell together by cooperation with the other member. 
Također je moguće da takvi tlačni elementi nisu u direktnom kontaktu s jednom od stijenki spremnika, već da oni deformiraju, na primjer, prstenasti i fleksibilan obruč s njegove unutarnje strane i da taj prsten sa svojim deformiranim dijelovima na svojoj vanjskoj strani pritisne zajedno stijenke tijela čaše i ljusku uz pomoć drugog elementa.
the presence of a detectable level of antibodies capable of immunospecific binding to Lymphocyte antigen 75 or said one or more epitope-containing fragments thereof in said subject as compared with a corresponding undetectable level in a healthy subject indicates the presence of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer in said subject. 
prisutnost razine protutijela koja se mogu detektirati i sposobna za imunospecifično vezanje na limfocitni antigen 75 ili navedeni jedan ili više fragmenata koji sadrže epitop u navedenom subjektu u usporedbi s odgovarajućom neodredivom razinom u zdravog subjekta ukazuje na prisutnost karcinoma jajnika ili karcinoma pluća kod navedenog subjekta.
A pharmaceutical tablet especially in accordance with the preceding claims having (a) a cracking force of at least 110 N, preferably 120 N, more preferably 130 N, and even more preferably 140 N, when subjected to an indentation test; (b) a penetration depth to crack distance of at least 1.0 mm, preferably 1.2 mm, more preferably 1.4 mm, and even more preferably 1.6 mm, when subjected to an indentation test; and (c) capable of resisting a work of at least 0.06 J without cracking. 
Farmaceutska tableta prema prethodnim zahtjevima naznačena time da ima (a) silu loma od najmanje 110 N, poželjno 120 N, poželjnije 130 N, te najpoželjnije 140 N, kada je podvrgnuta indentacijskom testu; (b) dubinu prodiranja s razmakom pukotine od najmanje 1.0 mm, poželjno 1.2 mm, poželjnije 1.4 mm, te najpoželjnije 1.6 mm, kada je podvrgnuta indentacijskom testu; te (c) da se može oduprijeti radu od najmanje 0.06 J bez loma. S Temperatura
The extended release dosage form of claim 19, wherein the dosage form comprises 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 120 mg or 160 mg of oxymorphone hydrochloride. 
Postupak prema zahtjevu 43, naznačen time da oblik davanja sadrži 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30, mg, 40 mg, 45 mg, 60 mg, ili 80 mg, 90 mg, 120 mg ili 160 mg oksimorfon hidroklorida.
incubating said starting liquid or said partly AX-REED treated liquid in said chamber, whereby the direction of electric field is reversed at intervals wherein steps d) and e) are performed at least partly simultaneously, and wherein the AX-REED membrane stack is connected to the CX-REED membrane stack in parallel, and wherein at least 65% of the at least one micro-nutrient is retained in the REED liquid. 
inkubiranje navedene početne tekućine ili navedene djelomično obrađene tekućine AX-REED u navedenoj komori, pri čemu se smjer električnog polja preokreće u intervalima pri čemu se koraci d) i e) provode barem djelomično istovremeno, i pri čemu je stog membrana AX-REED paralelno spojen na stog membrana CX-REED, te pri čemu je najmanje 65 % najmanje jedne mikro hranjive tvari zadržano u tekućini REED.
S-Vn-heteroaryl wherein n is 1, V is C1-C6 alkylene optionally substituted with C1-C6 alkyl, and heteroaryl is a 5-6 membered ring having 1-2 atoms independently selected from N, S and O; 
S-Vn-heteroaril gdje n je 1, V je C1-C6 alkilen po izboru supstituiran s C1-C6 alkil, i heteroaril je 5-6-eročlani prsten s 1-2 atoma nezavisno izabrana između N, S i O;
A medical kit for administering PLD in combination with ET-743, comprising a supply of PLD in dosage units, wherein each of said dosage units contains an amount of PLD for its therapeutically effective administration in combinations with ET-743; 
Medicinski komplet za primjenu PLD u kombinaciji sa ET-743, naznačen time, što sadrži zalihu PLD u jedinicama doze, pri čemu svaka od navedenih jedinica doze sadrži količinu PLD za njegovu terapeutski efikasnu primjenu u kombinacijama sa ET-743.
An isolated or recombinant fusion protein dimer comprising two monomeric fusion proteins linked via at least one disulfide bond formed between two cysteine residues present in each monomeric mutant fusion protein, wherein each monomeric fusion protein comprises (a) a polypeptide comprising a polypeptide sequence which differs from SEQ ID NO:50 in no more than 6 amino acid residues and which includes residues at positions 24, 30, 32, 41, 50, 54, 55, 56, 64, 65, 70, 85, 104 and 106 that are identical to the amino acid residues at the corresponding positions in SEQ ID NO:50 and (b) an Ig Fc polypeptide, and wherein the fusion protein dimer binds human CD80 or human CD86 or an extracellular domain of either and has a greater ability to suppress an immune response than a LEA29Y-Ig fusion protein dimer, wherein the LEA29Y-Ig fusion protein dimer comprises two monomeric LEA29Y-Ig fusion proteins each comprising the polypeptide sequence of SEQ ID NO: 166. 
Izolirani ili rekombinantni polipeptid koji sadrži polipeptidnu sekvencu koja se razlikuje od SEQ ID NO:36 u ne više od 6 aminokiselinskih ostataka i koja uključuje ostatke na položajima 24, 30, 32, 41, 50, 54, 55, 56, 64, 65, 70, 85, 104 i 106 koji su identični sa aminokiselinskim ostatcima na odgovarajućim položajima u SEQ ID NO:36, naznačen time da polipeptid veže humani CD80 ili humani CD86 ili izvanstaničnu domenu bilo kojeg od njih i ima sposobnost inhibicije imunološkog odgovora koja je veća od sposobnosti inhibicije imunološkog odgovora polipeptida LEA29Y koji sadrži polipeptidnu sekvencu koja je prikazana u SEQ ID NO:168.
is selected from formula II or formula III shown below: wherein Ra is hydrogen or methyl; or a pharmaceutically acceptable salt or solvate thereof. 
je odabran od dolje prikazane formule II ili formule III: [image] pri čemu Ra je vodik ili metil; ili njegove farmaceutski prihvatljive soli ili solvati.
is selected from the group consisting of -OH, ORa, and NRbRc; 
R! je odabran iz skupine koju čine -OH, OR*, i NR*R";
To a solution of the intermediate from step B (13 mg, 0.04 mmol) in MeOH (1 mL) was added formic acid (0.1 mL) followed by palladium black (10 mg). 
U otopinu intermedijera iz koraka B (13 mg, 0.04 mmol) u MeOH (1 mL) je dodana mravlja kiselina (0.1 mL) i zatim crni paladij (10 mg).
Dosage form according to any of claims 1 to 10 for use in the prophylaxis or treatment of a clinical conidition in a mammal, wherein the clinical condition is selected from the group of benign gastric ulcer, gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, duodenal ulcer, duodenal ulcer associated with Helicobacter pylori, prophylaxis of NSAID-associated gastric or duodenal ulcer in patients with an increased risk of gastroduodenal complication who require continued NSAID treatment and combination therapy with antibiotics in the eradication of Helicobacter pylori. 
Dozirni oblik prema bilo kojem od zahtjeva 1 do 10, naznačen time, da se upotrebljava za profilaksu ili liječenje kliničkog stanja kod sisavaca, gdje je kliničko stanje odabrano iz skupine koju čine: benigni gastrični ulkus, bolest gastro-ezofagealnog refluksa, Zollinger-Ellison-sindrom, duodenalni ulkus, duodenalni ulkus povezan s bakterijom Helicobacter pylori, profilaksa za gastrični ili duodenalni ulkus povezan s NSAID kod pacijenata s povećanim rizikom za gastroduodenalne komplikacije, koje zahtijevaju sustavno NSAID liječenje i kombinacijsku terapiju s antibioticima za eradikaciju bakterije Helicobacter pylori.
supplying the block made of a material suitable for manufacturing the dental prosthesis, the block provided with a hole; 
nabavka bloka (1) od materijala pogodnog za izradu zubne proteze i koji ima šupljinu (2),
A combination of donepezil or a pharmaceutically acceptable salt thereof, and 
L Kombinacija donepezila ili njegove farmaceutski prihvatljive soli i
• blow-moulding the heated preform to form a bag-in-container; characterized in that, during the blow-moulding process, the bag (21) is anchored to the outer layer (22) at least one point remote from said single opening. 
* oblikovanje u kalupu puhanjem zagrijanog predsklopa radi oblikovanja posude s vrećicom unutar nje; naznačen time da je, za vrijeme postupka oblikovanja u kalupu puhanjem, vrećica (21) pričvršćena na vanjski sloj
Said arch or arches form channels between the baking support and the lower side of the food product, which will allow hot air from the oven to envelope the food product in a more homogeneous manner. 
Slastice od tijesta, kroasani ili čokoladne rolice u skladu s patentnim zahtjevom 20, naznačene time, da navedeni višestruki lukovi tvore jedan ili više kanala između potpornja za pečenje 1 donje strane prehrambenog proizvoda.
4 . 6 and 8, the level of the apex of the ring bead (15) is sloped downwards toward the next adjacent portion of the peripheral wall (5) in accordance with the slope of the upper surface of the elevation (18) with reference to the radial level that is vertical to axis (14). 
Poklopac limenke u skladu s patentnim zahtjevom 1, naznačen time što je periferna stijenka (5) ploče poklopca (2) točka simetrična u odnosu na os (14), a unutarnja površina prstenaste stijenke (11) se svojom visinom pruža paralelno u odnosu na navedenu os u najmanju ruku u gornjem dijelu prstenaste stijenke.
Typically, unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of this invention. 
Jedinične dozne forme će tipično sadržavati otprilike 0.5 mg do 0.5 g spoja iz ovog izuma.
Cells were then incubated for 40 minutes with 2.3 µM of the ratiometric calcium binding dye fura-2/AM (from Molecular Probes), made up in HEPES buffered HBSS, containing 0.01% pluronic F-127. 
Zatim su stanice inkubirane 40 minuta s 2,3 uM ratiometrijske kalcijeve vežuće boje fura-2/AM (tvrtke Molecular Probes), pripravljene u HBSS-u puferiranom s HEPES-om, koji je sadržavao 0,01% pluronskog F127.
Thus, the invention can be applied to treat or prevent withdrawal from, e.g ., heroin, in a pregnant woman. 
Stoga se izum može primijeniti za liječenje ili sprječavanje ustezanja od, npr., heroina, kod trudne žene.
The floating lake system of claim 7, wherein the frame connectors are built out of flexible materials. 
Sustav plutajućeg jezera (1) prema zahtjevu 20, naznačen time što su spojnice okvira izrađene od savitljivih materijala.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of alcoholic or non-alcoholic steatohepatitis. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, naznačena/e time, da se upotrebljava(ju) u liječenju i/ili prevenciji autoimunog hepatitisa.
The compounds represented by the aforementioned formula (I) may form a salt. 
Spojevi prikazani gore navedenom formulom (I) mogu tvoriti sol.
The method according to claim 12, wherein the disease is selected from the group consisting of chronic pain, cancer pain, neuropathic pain, cold allodynia, postoperative pain, neuralgia, neuropathies, diabetic neuropathy, fibromyalgia, algesia, pain associated with nerve injury, migraine, headache, pain associated with osteoarthritis and rheumatoid arthritis, itch, irritable bowel disease, painful bladder syndrome, interstitial cystitis, detrusor overactivity, urinary incontinence, neurogenic detrusor overactivity, idiopathic detrusor overactivity, benign prostatic hyperplasia, lower urinary tract disorders, anxiety, depression and cold-induced/or exhacerbated pulmonary hypertension, COPD, asthma, epiphora and dry eye disease. 
Spoj za uporabu u skladu s patentnim zahtjevom 11, naznačen time da navedena bolest je odabrana od kronične boli, boli kod karcinoma, neuropatske boli, uključujući alodiniju na hladnoću, postoperativnu bol, neuralgiju, neuropatije, uključujući dijabetičku neuropatiju, fibromijalgiju, algeziju, bol povezanu s povredom živca, migrenu, glavobolju, bol povezanu sa osteoartritisom i reumatoidnim artritisom, svrab, iritabilnu bolest crijeva, sindrom bolnog mjehura, intersticijalni cistitis, prekomjernu aktivnost detrusora, urinarnu inkontinenciju, neurogenu prekomjernu aktivnost detrusora, idiopatsku prekomjernu aktivnost detruzora, benignu hiperplaziju prostate, poremećaje nižeg dijela urinarnog trakta i simptome kod nižeg dijela urinarnog trakta, anksioznost, depresiju i hladnoćom izazvanu/ili pogoršanu plućnu hipertenziju, COPD, astmu, epiforu i bolest suhog oka.
In a further embodiment R5 is phenyl substituted with one or more A, which A is selected from the group comprising halo, alkoxy, haloalkoxy, haloalkyl, alkyl, alkanol, cyano, phenoxy, alkylsulfonyl and (di)alkylamino. 
Spoj prema zahtjevu 5, naznačen time da se A odabire iz skupine koju sačinjavaju halo, alkoksi, haloalkoksi, haloalkil, alkil, alkanol, cijano, fenoksi, alkilsulfonil i (dijalkilamino.
The compound of claim 1, wherein the compound of formula (I) is a compound of formula (IA): 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj formule (I) spoj formule (IA): Ri
Formulations for injection may be presented in unit dosage form, such as in ampoules or in multi-dose containers, with an added preservative. 
Injekcijske formulacije može se prezentirati u obliku jedinice doziranja, primjerice u ampulama ili višedoznim spremnicima, uz dodatak konzervansa.